Orion Portfolio Solutions LLC acquired a new stake in GSK plc (NYSE:GSK – Get Rating) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 5,002 shares of the pharmaceutical company's stock, valued at approximately $218,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of GSK. JTC Employer Solutions Trustee Ltd raised its position in GSK by 50.4% during the 1st quarter. JTC Employer Solutions Trustee Ltd now owns 9,016,970 shares of the pharmaceutical company's stock worth $392,735,000 after buying an additional 3,023,634 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in GSK by 32.5% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 9,621,370 shares of the pharmaceutical company's stock worth $419,107,000 after buying an additional 2,362,274 shares during the last quarter. Goldman Sachs Group Inc. raised its position in GSK by 48.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 7,113,039 shares of the pharmaceutical company's stock worth $309,844,000 after buying an additional 2,316,204 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of GSK by 90.1% during the 1st quarter. Acadian Asset Management LLC now owns 3,400,013 shares of the pharmaceutical company's stock valued at $148,070,000 after purchasing an additional 1,611,899 shares in the last quarter. Finally, Fisher Asset Management LLC increased its holdings in shares of GSK by 4.1% during the 1st quarter. Fisher Asset Management LLC now owns 18,967,209 shares of the pharmaceutical company's stock valued at $826,212,000 after purchasing an additional 750,042 shares in the last quarter. 16.86% of the stock is owned by hedge funds and other institutional investors.
Get GSK alerts:GSK Trading Down 0.6 %
Shares of GSK opened at $28.66 on Wednesday. GSK plc has a 52-week low of $28.47 and a 52-week high of $46.97. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 0.83. The firm's fifty day moving average is $35.18 and its two-hundred day moving average is $40.69. The stock has a market cap of $58.29 billion, a PE ratio of 9.49, a price-to-earnings-growth ratio of 1.12 and a beta of 0.61.
GSK (NYSE:GSK – Get Rating) last announced its earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.76 by $0.11. GSK had a net margin of 12.91% and a return on equity of 27.84%. The company had revenue of $8.71 billion for the quarter, compared to analysts' expectations of $9.35 billion. Research analysts forecast that GSK plc will post 3.23 earnings per share for the current fiscal year.GSK Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 6th. Shareholders of record on Friday, August 19th will be paid a dividend of $0.383 per share. This represents a $1.53 annualized dividend and a yield of 5.35%. The ex-dividend date is Thursday, August 18th. This is a boost from GSK's previous quarterly dividend of $0.35. GSK's payout ratio is 50.66%.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on the stock. Jefferies Financial Group lowered shares of GSK from a "buy" rating to a "hold" rating in a report on Thursday, September 8th. UBS Group cut their target price on shares of GSK from GBX 1,876 ($22.67) to GBX 1,850 ($22.35) in a report on Wednesday, July 20th. Credit Suisse Group raised shares of GSK from an "underperform" rating to a "neutral" rating in a report on Thursday, September 15th. Deutsche Bank Aktiengesellschaft cut their target price on shares of GSK from GBX 1,750 ($21.15) to GBX 1,500 ($18.12) in a report on Wednesday, September 7th. Finally, Morgan Stanley dropped their price target on shares of GSK from GBX 1,860 ($22.47) to GBX 1,550 ($18.73) in a research note on Wednesday, September 7th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $1,700.00.
GSK Profile
(Get Rating)
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Articles
- Get a free copy of the StockNews.com research report on GSK (GSK)
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- Will UPS Be Next to Deliver a Warning?
- Is This the Darkest Before the Dawn for Gap Stock?
- Build A Better Tech Portfolio With Jabil Inc.
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.